Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with China’s Hansoh Pharmaceuticals Group Company to acquire exclusive clinical ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

TARRYTOWN, N.Y. - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a prominent biotechnology company with annual revenue of $14.1 billion and strong financial health according to InvestingPro ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...

Regeneron inks $80 million deal with Hansoh for Phase 3 ... Regeneron inks $80 million deal with Hansoh for Phase 3 obesity trial, ... Sanofi Stock Falls After Uneven Smoker’s Lung Drug Data.

REGN inks a $2B-plus obesity drug deal with Hansoh, ... Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market.

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid ...

TARRYTOWN, N.Y. - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a prominent biotechnology company with annual revenue of $14.1 billion and strong financial health according to InvestingPro analysis, ...

REGN inks a $2B-plus obesity drug deal with Hansoh, ... Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market.